PMCPA PRESS RELEASE 14 July 2025 - Case ruled in breach of Clause 2
LEO Pharma has breached the ABPI Code of Practice for the Pharmaceutical Industry and brought discredit upon, and reduced confidence in, the pharmaceutical industry.
Press Release 15 July 2025
LEO Pharma - Case/0349/11/24 and Case/0350/11/24
For the inclusion of inaccurate and misleading information in the ‘Tinzahelp administration’ app for patients prescribed tinzaparin sodium, and a failure to withdraw such information immediately, LEO Pharma was ruled in breach of the following clauses of the 2024 Code:
Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry
Clause 5.1 - Failing to maintain high standards
Clause 6.1 - Providing misleading information
Clause 26.2 - Providing inaccurate information about a prescription only medicine to the public
The case report is available at www.pmcpa.org.uk.
Ends
Notes to Editors:
Notes to Editors:
The advertisement will appear in the BMJ and the Nursing Standard in December 2025.
Media Contacts:
For more information contact Mailbox - info@pmcpa.org.uk
The Prescription Medicines Code of Practice Authority (PMCPA) was established by The Association of the British Pharmaceutical Industry (ABPI) to operate the ABPI Code of Practice for the Pharmaceutical Industry independently of the ABPI. The PMCPA is a division of the ABPI. The Code covers the promotion of medicines for prescribing to health professionals and the provision of information to the public about prescription only medicines.
If you have any concerns about the activities of pharmaceutical companies in this regard, please contact the PMCPA at 2nd Floor, Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB, email: complaints@pmcpa.org.uk, or visit www.pmcpa.org.uk/complaints-procedure/make-a-complaint.
The Code and other information, including details about ongoing cases, can be found on the PMCPA website: www.pmcpa.org.uk.